Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;192(3):425-432.
doi: 10.1111/bjh.17041. Epub 2020 Aug 14.

Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation

James S Castleman  1 , Kenneth J Moise Jr  2 , Mark D Kilby  1   3
Affiliations
Review

Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation

James S Castleman et al. Br J Haematol. 2021 Feb.

Abstract

Haemolytic disease of the fetus and newborn (HDFN) remains an important cause of fetal mortality with potential neonatal and longer-term morbidity. HDFN is caused by maternal red cell alloimmunisation, with IgG antibodies crossing the placenta to destroy fetal erythroid cells expressing the involved antigen. Intrauterine fetal blood transfusion is the therapy of choice for severe fetal anaemia. Despite a strong evidence base and technical advances, invasive fetal therapy carries risk of miscarriage and preterm birth. Procedure-related risks are increased when invasive, in utero transfusion is instituted prior to 22 weeks to treat severe early-onset fetal anaemia. This review focuses upon this cohort of HDFN and discusses intravenous immunoglobin (IVIg) and novel monoclonal antibody (M281, nipocalimab) treatments which, if started at the end of the first trimester, may attenuate the transplacental passage and fetal effects of IgG antibodies. Such therapy has the ability to improve fetal survival in this severe presentation of HDFN when early in utero transfusion may be required and may have wider implications for the perinatal management in general.

Keywords: anti-D; clinical trials; fetal blood; fetal medicine; immune haemolytic anaemia.

PubMed Disclaimer

References

    1. Castleman JS, Gurney LRI, Kilby MD, Morris RK. Identification and management of fetal anaemia: a practical guide. Obstet Gynaecol. 2020. (in press)
    1. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn. 2009;29:101-7.
    1. Delaney M, Wikman A, van de Watering L, Schonewille H, Verdoes JP, Emery SP, et al. Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study. Transfusion. 2017;57:525-32.
    1. Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, et al. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database. Br J Haematol. 2018;181:672-81.
    1. Evers D, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016;3:e284-92.

Substances